The Bloom #177 Free Edition interwoven web

Give me one minute, and I will find you just about any psychedelic research paper you're looking for.

But if you're on the hunt for stakeholders in the psychedelic landscape, I often won't be able to tell you who-is-who.

I hope to change that soon. To that purpose, I've just released the first text-only psychedelic landscape map.

Please let me know what areas I'm missing, what needs to be reworded, etc. Just reply to this email or send me an email at floris@blossomact.com.

Floris - Founder of Blossom

ps In just over two weeks' time, on May 15th, Psychedelics Design will host the first Psychedelics Design Awards. It's going to be an inspiring event featuring great speakers and the one and only Dennis Walker as host. Check it out and get tickets here, use code BLOSSOM30 for a 30% discount.

​

Latest Psychedelic Research

1 Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program​

This real-world study (n=185) found that oral esketamine (35-210mg/70kg; 6w; 12x) was effective and well-tolerated in severely treatment-resistant depression (TRD) patients, showing significant symptom improvement with minimal dropouts (7.6%), suggesting it could be a viable alternative to intranasal or intravenous administration.

2 Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression​

This open-label fixed-order dose-escalation trial (n=14) evaluated inhaled DMT (15mg & 60mg) for treatment-resistant depression (TRD) for the first time. Results showed rapid and sustained antidepressant effects with a 21-point reduction on the Montgomery-Asberg Depression Rating Scale by day 7 (p<0.001), an 86% response rate, and a 57% remission rate lasting up to 3 months, with significant decreases in suicidal ideation (SI).

3 Efficacy and safety of esketamine for smoking cessation among patients diagnosed with lung cancer and major depression disorder: A randomized, placebo-controlled clinical trial​

This multicenter, randomised, placebo-controlled clinical trial (n=236) investigates the efficacy and safety of esketamine (ESK) (8x35mg) for smoking cessation in patients with lung cancer and major depressive disorder (MDD). Eight weekly intranasal ESK sessions significantly improved both self-reported (44.1%) and biologically verified (28.8%) smoking abstinence at 6-month follow-up, alongside reductions in depression, anxiety, nicotine dependence, and respiratory symptoms.

More Research

• ​The Rise of Psilocybin Use in the United States: A Multisource Observational Study​
• ​Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises​
• ​Exploring 5-MeO-DMT as a pharmacological model for deconstructed consciousness​
• ​Prediction of hallucinogen persisting perception disorder and thought disturbance symptoms following psychedelic use​

New on Blossom

1 Psychedelic Landscape – Request for Feedback​

For the past six years, Blossom has tracked all psychedelic research and distilled the findings for researchers, clinicians and the curious. Along the way, we noticed a glaring gap: knowing what the science says is only half the story—understanding who can turn that science into real-world impact is the other half. Today, we are closing that gap with the first public draft of our Psychedelic Landscape Map.

Please review it on the site and send me your feedback.

2 Psychedelics and Postpartum Depression​

Postpartum depression (PPD) is a distinct condition from major depressive disorder, affecting 10-20% of mothers worldwide and characterised by emotional disconnection from self, baby, and support systems, with both biological and psychosocial origins.

Ketamine and esketamine have shown promising initial results in preventing postpartum depression (PPD), with one study showing that esketamine reduces the major PPD risk to 7% compared to 25% in the placebo group. However, more research is needed on optimal dosing and safety during breastfeeding.

Several companies are actively advancing psychedelic treatments for PPD, with Reunion Neuroscience developing RE104 (a short-duration psilocybin analogue) and GH Research studying GH001 (inhalable 5-MeO-DMT), both showing encouraging preliminary results in clinical trials.

3 Psychedelic Research Links 2025​

A comprehensive overview of all psychedelic research that has come out this year. We cover the research per month and provide a one-sentence summary for each new publication. After the full summary is added, a link to Blossom's review is added to the papers included in our database.
​

Spotlight

1 Psychedelics Design Awards (Event)

The Psychedelics Design Awards, scheduled for May 15, 2025, will bring together pioneers exploring the intersection of psychedelics, design, and social impact. This inaugural online event will showcase projects that leverage altered states of consciousness for creative problem-solving, harm reduction initiatives, and regenerative future planning. The half-day ceremony will feature thought leaders from organizations including the Center for MINDS, Zendo Project, MAPS, Wavepaths, and Psychedelics Today.

Panel discussions will explore several critical areas, including responsible approaches to harm reduction, the therapeutic role of music during psychedelic experiences, novel approaches to creativity, and design principles for ecological sustainability. The event will begin with opening remarks from Dr. Bruce Damer, co-founder of MINDS and researcher at UC Santa Cruz, offering scientific context for the innovative work being recognized across seven award categories covering architectural design, experimental concepts, and audio experiences.

Among the notable presenters are Chelsea Rose Pires and Jessa Hurst from Zendo Project discussing compassionate care strategies, Mendel Kaelen of Wavepaths exploring music in therapeutic settings, and Joe Moore from Psychedelics Today examining how design might contribute to ecological healing.

Learn more and attend the event with code BLOSSOM30:
​https://www.psychedelics.design/psychedelics-design-online-awards-ceremony​

Molenvaart 76, Anna Paulowna, NH 1761AL
​Unsubscribe · Preferences​